Development of ELISAs for quantification of HMFG1-specific human anti-mouse IgG and IgM antibodiesOEI, A. L. M; BOERMAN, O. C; GEURTS-MOESPOT, A et al.The International journal of biological markers. 2007, Vol 22, Num 3, pp 167-171, issn 0393-6155, 5 p.Article

Abnormal cervical cytology in women eligible for IVFVAN HAMONT, D; NISSEN, L. H. C; SIEBERS, A. G et al.Human reproduction (Oxford. Print). 2006, Vol 21, Num 9, pp 2359-2363, issn 0268-1161, 5 p.Article

Leiomyomatosis peritonealis disseminata : Does malignant transformation occur? A literature reviewBEKKERS, R. L. M; WILLEMSEN, W. N. P; SCHIJF, C. P. T et al.Gynecologic oncology (Print). 1999, Vol 75, Num 1, pp 158-163, issn 0090-8258Article

Tumour targeting of the anti-ovarian carcinoma X anti-CD3/TCR bispesific monoclonal antibody OC/TR and its parental MOv18 antibody in experimental ovarian cancerBOERMAN, O. C; TIBBEN, J. G; MASSUGER, L. F. A. G et al.Anticancer research. 1995, Vol 15, Num 5B, pp 2169-2174, issn 0250-7005Article

Clinical applications of monoclonal antibodies against ovarian cancer-associated antigensKENEMANS, P; YEDEMA, C. A; HILGERS, J. H. M et al.European journal of obstetrics, gynecology, and reproductive biology. 1988, Vol 29, Num 3, pp 207-218, issn 0301-2115Article

External validation of three prognostic models for overall survival in patients with advanced-stage epithelial ovarian cancerVAN DE LAAR, R; INTHOUT, J; VAN GORP, T et al.British journal of cancer. 2014, Vol 110, Num 1, pp 42-48, issn 0007-0920, 7 p.Article

Comparing cisplatin-based combination chemotherapy with EMA/CO chemotherapy for the treatment of high risk gestational trophoblastic neoplasiaLYBOL, C; THOMAS, C. M. G; OTTEVANGER, P. B et al.European journal of cancer (1990). 2013, Vol 49, Num 4, pp 860-867, issn 0959-8049, 8 p.Article

Trends in incidence and survival of Dutch women with vulvar squamous cell carcinomaSCHUURMAN, M. S; VAN DEN EINDEN, L. C. G; MASSUGER, L. F. A. G et al.European journal of cancer (1990). 2013, Vol 49, Num 18, pp 3872-3880, issn 0959-8049, 9 p.Article

Clinical utility of hyperglycosylated hCG in serum taken before hydatidiform mole evacuation to predict persistent trophoblastic diseaseNGO DUC, H; VAN TROMMEL, N. E; SWEEP, F. C. G. J et al.The International journal of biological markers. 2006, Vol 21, Num 1, pp 45-49, issn 0393-6155, 5 p.Article

Tissue distribution of ^99mTc, ¹¹¹In and ¹²³I-OV-TL 3 Fab' in ovarian carcinoma bearing nude miceMASSUGER, L. F. A. G; CLAESSENS, R. A. M. J; PAK, Y. K et al.International journal of radiation applications and instrumentation. Part B. Nuclear medicine and biology. 1991, Vol 18, Num 1, pp 77-83, issn 0883-2897, 6 p.Conference Paper

Immunoscintigraphy of ovarian cancer with indium-111-labeled OV-TL 3F(ab')₂ monoclonal antibodyMASSUGER, L. F. A. G; KENEMANS, P; CLAESSENS, R. A. M. J et al.The Journal of nuclear medicine (1978). 1990, Vol 31, Num 11, pp 1802-1810, issn 0161-5505Article

Biological behavior of CIN lesions is predictable by multiple parameter logistic regression modelsVAN HAMONT, D; BULTEN, J; SHIRANGO, H et al.Carcinogenesis (New York. Print). 2008, Vol 29, Num 4, pp 840-845, issn 0143-3334, 6 p.Article

¹H-magnetic Resonance spectroscopy : A new technique to discriminate benign from malignant ovarian tumorsMASSUGER, L. F. A. G; VAN VIERZEN, P. B. J; ENGELKE, U et al.Cancer. 1998, Vol 82, Num 9, pp 1726-1730, issn 0008-543XArticle

Fast dynamic contrast enhanced MR imaging of cervical carcinomaVAN VIERZEN, P. B. J; MASSUGER, L. F. A. G; RUYS, S. H. J et al.Clinical radiology. 1998, Vol 53, Num 3, pp 183-192, issn 0009-9260Article

Ovarian cancer incidence (1989-1991) and mortality (1954-1993) in the NetherlandsKOPER, N. P; KIEMENEY, A. L. M; MASSUGER, L. F. A. G et al.Obstetrics and gynecology (New York. 1953). 1996, Vol 88, Num 3, pp 387-393, issn 0029-7844Article

Decreased Kidney uptake of Technetium-99m-labelled Fab' fragments in ovarian carcinoma bearing nude mice using a cleavable chelatorTIBBEN, J. G; MASSUGER, L. F. A. G; BOERMAN, O. C et al.Nuclear medicine and biology. 1994, Vol 21, Num 1, pp 17-24, issn 0969-8051Article

Specific and nonspecific immunoassays to detect HAMA after administration of Indium-111-labeled OV-TL 3 F(ab')₂ monoclonal antibody to patients with ovarian cancerMASSUGER, L. F. A. G; THOMAS, C. M. G; SEGERS, M. F. G et al.JNM : (1990). 1992, Vol 33, Num 11, pp 1958-1963Article

Biodistribution of iodine-125 and indium-111 labeled OV-TL 3 intact antibodies and F(ab')₂ fragments in tumor-bearing athymic miceMASSUGER, L. F. A. G; BOERMAN, O. C; CORSTENS, F. H. M et al.Anticancer research. 1991, Vol 11, Num 6, pp 2051-2057, issn 0250-7005Article

Human chorionic gonadotropin (hCG) regression normograms for patients with high-risk gestational trophoblastic neoplasia treated with EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide and vincristine) chemotherapyLYBOL, C; WESTERDIJK, K; SWEEP, F. C. G. J et al.Annals of oncology. 2012, Vol 23, Num 11, pp 2903-2906, issn 0923-7534, 4 p.Article

Significant decrease of adenocarcinoma in situ not reflected in cervical adenocarcinoma incidence in the Netherlands 1989-2003VAN DE NIEUWENHOF, H. P; MASSUGER, L. F. A. G; DE HULLU, J. A et al.British journal of cancer. 2008, Vol 98, Num 1, pp 165-167, issn 0007-0920, 3 p.Article

Uterine malignant leiomyoblastoma (epithelioid leiomyosarcoma) during pregnancyBEKKERS, R. L. M; MASSUGER, L. F. A. G; BERG, P. P. V. D et al.Gynecologic oncology (Print). 1999, Vol 72, Num 3, pp 433-436, issn 0090-8258Conference Paper

Cytologic examination to detect clear cell adenocarcinoma of the vagina or cervixHANSELAAR, A. G. J. M; BOSS, E. A; MASSUGER, L. F. A. G et al.Gynecologic oncology (Print). 1999, Vol 75, Num 3, pp 338-344, issn 0090-8258Article

Comparison of four 'second generation' immunoassay systems to determine CA 125 in serum by using a graphical approach to method comparison analysisKOPER, N. P; THOMAS, C. M. G; MASSUGER, L. F. A. G et al.European journal of clinical chemistry and clinical biochemistry. 1997, Vol 35, Num 8, pp 617-623, issn 0939-4974Article

Improvement of clinical staging in cervical cancer with serum squamous cell carcinoma antigen and CA 125 determinationsMASSUGER, L. F. A. G; KOPER, N. P; THOMAS, C. M. G et al.Gynecologic oncology (Print). 1997, Vol 64, Num 3, pp 473-476, issn 0090-8258Article

Dosimetric evaluation of immunoscintigraphy using indium-111-labeled monoclonal antibody fragments in patients with ovarian cancerBUIJS, W. C. A. M; MASSUGER, L. F. A. G; CLAESSENS, R. A. M. J et al.JNM : (1990). 1992, Vol 33, Num 6, pp 1113-1120Article